Cargando…
Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein
Bovine papillomavirus type 1 L1 protein was produced in a baculovirus expression system and purified as virus-like particles (VLPs) by affinity chromatography using lectins. The morphological integrity of VLPs was confirmed by electron microscopy. Differences between the two detected variants were d...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086343/ https://www.ncbi.nlm.nih.gov/pubmed/37056230 http://dx.doi.org/10.3389/fvets.2023.1116661 |
_version_ | 1785022131111723008 |
---|---|
author | Vrablikova, Alena Brezani, Veronika Psikal, Ivan Fraiberk, Martin Sebela, Marek Fojtikova, Martina Kulich, Pavel Hezova, Renata Masek, Josef |
author_facet | Vrablikova, Alena Brezani, Veronika Psikal, Ivan Fraiberk, Martin Sebela, Marek Fojtikova, Martina Kulich, Pavel Hezova, Renata Masek, Josef |
author_sort | Vrablikova, Alena |
collection | PubMed |
description | Bovine papillomavirus type 1 L1 protein was produced in a baculovirus expression system and purified as virus-like particles (VLPs) by affinity chromatography using lectins. The morphological integrity of VLPs was confirmed by electron microscopy. Differences between the two detected variants were deciphered by mass spectrometry of peptides (MALDI-TOF). Mice were immunized with purified VLPs in doses of 10, 25, or 50 μg in combination with 1% saponin and 15% alhydrogel per dose as adjuvants. Analysis of the humoral immune response revealed increased levels of specific antibodies detected 3 weeks after the first immunization in all groups of animals. This was further significantly increased by the booster applied 3 weeks after the first dose, with the best immune response in a group of mice immunized by the largest dose of antigen. BPV1 L1 VLPs purified by affinity chromatography using lectins could be used for prophylactic immunization in veterinary medicine. |
format | Online Article Text |
id | pubmed-10086343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100863432023-04-12 Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein Vrablikova, Alena Brezani, Veronika Psikal, Ivan Fraiberk, Martin Sebela, Marek Fojtikova, Martina Kulich, Pavel Hezova, Renata Masek, Josef Front Vet Sci Veterinary Science Bovine papillomavirus type 1 L1 protein was produced in a baculovirus expression system and purified as virus-like particles (VLPs) by affinity chromatography using lectins. The morphological integrity of VLPs was confirmed by electron microscopy. Differences between the two detected variants were deciphered by mass spectrometry of peptides (MALDI-TOF). Mice were immunized with purified VLPs in doses of 10, 25, or 50 μg in combination with 1% saponin and 15% alhydrogel per dose as adjuvants. Analysis of the humoral immune response revealed increased levels of specific antibodies detected 3 weeks after the first immunization in all groups of animals. This was further significantly increased by the booster applied 3 weeks after the first dose, with the best immune response in a group of mice immunized by the largest dose of antigen. BPV1 L1 VLPs purified by affinity chromatography using lectins could be used for prophylactic immunization in veterinary medicine. Frontiers Media S.A. 2023-03-28 /pmc/articles/PMC10086343/ /pubmed/37056230 http://dx.doi.org/10.3389/fvets.2023.1116661 Text en Copyright © 2023 Vrablikova, Brezani, Psikal, Fraiberk, Sebela, Fojtikova, Kulich, Hezova and Masek. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Veterinary Science Vrablikova, Alena Brezani, Veronika Psikal, Ivan Fraiberk, Martin Sebela, Marek Fojtikova, Martina Kulich, Pavel Hezova, Renata Masek, Josef Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein |
title | Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein |
title_full | Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein |
title_fullStr | Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein |
title_full_unstemmed | Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein |
title_short | Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein |
title_sort | development of modern immunization agent against bovine papillomavirus type 1 infection based on bpv1 l1 recombinant protein |
topic | Veterinary Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086343/ https://www.ncbi.nlm.nih.gov/pubmed/37056230 http://dx.doi.org/10.3389/fvets.2023.1116661 |
work_keys_str_mv | AT vrablikovaalena developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein AT brezaniveronika developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein AT psikalivan developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein AT fraiberkmartin developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein AT sebelamarek developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein AT fojtikovamartina developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein AT kulichpavel developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein AT hezovarenata developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein AT masekjosef developmentofmodernimmunizationagentagainstbovinepapillomavirustype1infectionbasedonbpv1l1recombinantprotein |